Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce first quarter 2012 earnings on Thursday April 26, 2012.
|Results press release will be issued at:||12:00 BST / 07:00 EDT|
|Investor conference call time:||14:00 BST / 09:00 EDT|
Live conference call for investors:
Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:00 BST/9:00 EDT.
The details of the conference call are as follows:
|UK dial in:||0800 077 8492 or 0844 335 0351|
|US dial in||1 866 8048688 or 1 718 3541175|
|International dial in:||+44 844 335 0351|
|Global Access Numbers:||http://www.btconferencing.com/globalaccess/?bid=54_attended|
|Password/Conf ID:||338 270|
A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details can be found on our Investor Relations website .
For further information please contact:
|Investor Relations||Souheil Salah (firstname.lastname@example.org)||+44 1256 894 160|
|Erin K. Kelly (email@example.com)||+1 781 482 9541|
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.